Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis

Biochemical and Biophysical Research Communications
Yalin ChenYajun Guo

Abstract

Despite the effectiveness of the anti-CD20 chimeric antibody (mAb), rituximab, in treating B-cell lymphomas, its efficacy remains variable and often modest. Hu8E4 is an anti-CD20 humanized antibody which exhibits markedly higher antitumor activity compared with rituximab. Previous studies have indicated that rituximab and almost all known anti-CD20 murine mAbs recognize the A170/P172 motif within the large extracellular loop of CD20. In this study, we demonstrated that hu8E4 also recognized the A170/P172 motif, suggesting that the epitopes recognized by rituximab and hu8E4 are very similar. Based on this, three single mutations (D57E, Y102K and Y102T) at the heavy chain variable region that can improve the affinity of rituximab were transferred to hu8E4. The results showed that D57E and Y102T but not Y102K successfully enhanced the binding of hu8E4 to CD20. Out of these hu8E4 mutants, hu8E4D57E exhibited the highest affinity. The in vitro and in vivo antitumor activity of hu8E4D57E was further investigated. Our data indicated that hu8E4D57E was as effective as hu8E4 in mediating CDC and inducing apoptosis in B-lymphoma cells, but it was more potent in ADCC than hu8E4. Importantly, hu8E4D57E was shown to be significantly more ef...Continue Reading

References

Jan 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·T F TedderH Saito
Sep 1, 1994·Immunology Today·T F Tedder, P Engel
Nov 18, 1998·Current Opinion in Oncology·G A Leget, M S Czuczman
Jun 24, 2003·Drug Discovery Today·Martin J Glennie, Jan G J van de Winkel
Jul 1, 2004·Blood·Guillaume CartronPhilippe Solal-Celigny
Jul 28, 2006·CA: a Cancer Journal for Clinicians·Robert M Sharkey, David M Goldenberg
Mar 31, 2007·The Journal of Biological Chemistry·Jiamu DuJianping Ding
Sep 5, 2007·Molecular Immunology·Martin J GlennieRonald P Taylor
Mar 19, 2008·Molecular Immunology·Jiamu DuJianping Ding
Dec 17, 2009·The Journal of Biological Chemistry·Bohua LiYajun Guo

❮ Previous
Next ❯

Citations

Jun 23, 2016·Oncotarget·Meng ShenXiubao Ren
Jul 3, 2021·Cancers·Anne-Laure DésageMarios E Froudarakis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.